Answers are grounded in this paper and cite their sources.
Synthesis and characterization of [(PNIPAM)-b-(Gly)] and mesoporous silica nanoparticles (MP-SiO 2 NPs) were carried out separately and used to develop [(PNIPAM)-b-(Gly)]-(MP-SiO 2 NPs). The synthesized MP-SiO 2 NPs were meso porous in nature. The size of SiO 2 NPs is in the range of ~180–250 nm (in diameter) with an average pore size of 2.8 nm within the particles. Interestingly, these mesoporous SiO 2 NPs were loaded with anticancer drug (ITM-imatinib mesylate) fallow by the incubation for 24 h at RT. However, ITM loaded MP-SiO 2 NPs were capped or covered with synthesized [(PNIPAM)-b-(Gly)] thin film. Here, thin film acts as protective layer for drug loaded MP-SiO 2 NPs, with that leakage of drug molecules throughout its transport pathway can be avoided. Significantly, thermosensitive [(PNIPAM)-b-(Gly)] polymer thin film depletes at body temperature (~37 °C) and drug molecules come out from the pores of SiO 2 NPs. However, developed [(PNIPAM)-b-(Gly)]-(MP-SiO 2 NPs) is compatible and used for cell inhibition studies. After 24 h treatment, drug ITM released from [(PNIPAM)-b-(Gly)]-(MP-SiO 2 NPs) shows significant (>90%) inhibition on leukemia blood cancer (K562) cells.
No takes yet. Share an insight, caveat, or question.
Amgoth et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: